17 results about "Bioresorbable polymers" patented technology

A polymer scaffold includes a porous component having a network of resorbable polymer fibers, and a therapeutic dispersed in the porous component, the therapeutic component including at least one of a plurality of cells, a plurality of drug particles, or a plurality of metallic nanoparticles.

To provide implantable polymer depots for controlled release of therapeutic agents.SOLUTION: The present technology relates to a depot assembly for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having: a therapeutic region comprising a therapeutic agent; and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to form diffusion openings in the control region when the depot is placed in vivo. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for 3 days or more.SELECTED DRAWING: None

Provided herein are bioresorbable, bioregenerative composite materials and compositions to regenerate tissues or organs to repair tissue or organ defects and constructs printed from the same as 3D structures shaped and sized to fill a tissue or organ defect. The composite materials are bioresorbable polymers, for example, polycaprolactone, and a bioresorbable graft material, for example, demineralized bone matrix. Also provided are methods for making the composite materials and compositions and methods for regenerating tissues or organs and repairing a tissue or organ defect using the constructs.

The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

The present invention provides a method of preventing blood coagulation comprising administering to a subject in need thereof an effective amount of ginsenoside compound K (CK). The invention also provides an application of the ginsenoside compound K (CK) in preparation of a medicine for preventing blood coagulation. Further, the present invention provides a drug-eluting percutaneous coronary intervention therapy (PCI) comprising a vascular implant wherein a surface of the vascular implant is coated with a first layer comprising a ginsenoside compound K (CK) and a first bioresorbable polymer, wherein the first bioabsorbable polymer comprises poly-L-lactic acid (PLLA) and poly (L-lactide-co-epsilon-caprolactone) (PLCL) in a weight ratio of 60% to 80%: 20% to 40%.

The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

A vascular implant. comprising a polymeric filter body having a central longitudinal axis and configured to be placed in a patient's blood conveying vessel portion. The filter body has a head and an outer periphery. Multiple filter legs extend both radially and longitudinally from said head. Each leg tapes between the axis and said outer periphery. Each leg has a proximal end portion next to the head and a distal portion with an anchor for engaging a vessel wall. A weakened break point is on one or more of the legs. The filter body and legs are 3D printed of a bioresorbable polymer.

An implantable medical device includes a mesh substrate. A first coating that covers at least a portion of the substrate. The first coating includes a first biodegradable or bioresorbable polymer. The first coating has a chemotherapeutic agent dispersed in the first polymer such that the first polymer releases the agent as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second biodegradable or bioresorbable polymer. The second coating has an antibiotic agent dispersed in the second polymer such that the second polymer releases the agent as the second polymer degrades. The first coating is configured to release the chemotherapeutic agent over about 10-180 days and the second coating is configured to release the antibiotic agent over about 3-10 days.

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and / or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

To provide depots for treatment of postoperative pain via sustained, controlled release of a therapeutic agent.SOLUTION: In some embodiments, a depot may comprise a therapeutic region comprising an analgesic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for 3 or more days.SELECTED DRAWING: None

Methods of repairing composite tissue injuries susceptible to adipocyte infiltration, by applying to the injury an electrospun polymer fiber scaffold comprising biocompatible and bioresorbable polymer fibers that are blended with an amount of a GSK-3 inhibitor that is effective to inhibit the infiltration of adipocytes into the scaffold and tissue. Polymer scaffolds blended with an amount of a GSK-3 inhibitor that is effective to inhibit the infiltration of adipocytes into the scaffold and tissue are also disclosed as are kits containing the scaffolds and stem cells for repairing tissue at the injury site.

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

A polymer scaffold includes a porous component having a network of resorbable polymer fibers, and a therapeutic dispersed in the porous component, the therapeutic component including at least one of a plurality of cells, a plurality of drug particles, or a plurality of metallic nanoparticles.

The present disclosure provides bioabsorbable particles with nucleic acids. The bioresorbable particle further includes a bioresorbable polymer matrix and a lipid salt, both of which can be altered to affect particle properties. The bioresorbable particles may be administered to a patient to treat a disease. Methods of making and using the bioabsorbable particles thereof are also provided.

The present invention is directed to bioresorbable polymer blend compositions with tunable mechanical properties for manufacturing medical devices. These blends are multicomponent blends, comprise multiple polymer components and may or may not require additives in the form of fibers or particles for the potential enhancement of mechanical and / or biological properties.